Compare BKTI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKTI | SLGL |
|---|---|---|
| Founded | 1997 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.9M | 247.1M |
| IPO Year | 2000 | 2016 |
| Metric | BKTI | SLGL |
|---|---|---|
| Price | $83.26 | $79.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $74.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 47.8K | 21.2K |
| Earning Date | 05-12-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.89 | N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $74,094,000.00 | N/A |
| Revenue This Year | $10.83 | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $22.13 | ★ N/A |
| Revenue Growth | ★ 45.42 | N/A |
| 52 Week Low | $35.76 | $0.40 |
| 52 Week High | $89.50 | $97.97 |
| Indicator | BKTI | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 49.79 |
| Support Level | $73.60 | $66.47 |
| Resistance Level | $87.21 | $95.83 |
| Average True Range (ATR) | 4.25 | 9.59 |
| MACD | 0.04 | -0.37 |
| Stochastic Oscillator | 97.33 | 50.91 |
BK Technologies Corp is a holding company that, through BK Technologies, Inc., its operating subsidiary, provides public safety-grade communications products and services designed to make first responders safer and more efficient. All operating activities described herein are undertaken by its operating subsidiary. The Company has one reportable segment - Land Mobile Radio (LMR) Products and Solutions. The LMR segment provides radio devices that are hand-held (portable) or installed in vehicles (mobile) and operate on private radio systems that are P25 compliant. The Company derives revenue in North America and manages the business activities on a consolidated basis.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.